Crucially, we demonstrated that pharmacological inhibition of USP13 sensitises HPV positive cervical cancer cells to BH3 mimetic inhibitors, suggesting that the targeting of USP13 may have therapeutic benefit in these cancers. The gene discussed is USP13; the disease is cervical cancer.